全文获取类型
收费全文 | 177360篇 |
免费 | 16539篇 |
国内免费 | 8225篇 |
专业分类
耳鼻咽喉 | 1128篇 |
儿科学 | 2570篇 |
妇产科学 | 1874篇 |
基础医学 | 37193篇 |
口腔科学 | 3937篇 |
临床医学 | 15846篇 |
内科学 | 32438篇 |
皮肤病学 | 2198篇 |
神经病学 | 12124篇 |
特种医学 | 6435篇 |
外国民族医学 | 34篇 |
外科学 | 15997篇 |
综合类 | 27449篇 |
现状与发展 | 27篇 |
一般理论 | 2篇 |
预防医学 | 5996篇 |
眼科学 | 3493篇 |
药学 | 17150篇 |
69篇 | |
中国医学 | 5916篇 |
肿瘤学 | 10248篇 |
出版年
2024年 | 335篇 |
2023年 | 2226篇 |
2022年 | 4393篇 |
2021年 | 6216篇 |
2020年 | 6115篇 |
2019年 | 5384篇 |
2018年 | 5540篇 |
2017年 | 5990篇 |
2016年 | 6484篇 |
2015年 | 6971篇 |
2014年 | 11229篇 |
2013年 | 13407篇 |
2012年 | 10412篇 |
2011年 | 11699篇 |
2010年 | 9523篇 |
2009年 | 9062篇 |
2008年 | 9158篇 |
2007年 | 9263篇 |
2006年 | 8479篇 |
2005年 | 7305篇 |
2004年 | 6243篇 |
2003年 | 5317篇 |
2002年 | 4188篇 |
2001年 | 3631篇 |
2000年 | 3071篇 |
1999年 | 2721篇 |
1998年 | 2579篇 |
1997年 | 2469篇 |
1996年 | 2287篇 |
1995年 | 2185篇 |
1994年 | 1993篇 |
1993年 | 1707篇 |
1992年 | 1510篇 |
1991年 | 1406篇 |
1990年 | 1220篇 |
1989年 | 1138篇 |
1988年 | 981篇 |
1987年 | 897篇 |
1986年 | 772篇 |
1985年 | 1113篇 |
1984年 | 972篇 |
1983年 | 628篇 |
1982年 | 823篇 |
1981年 | 665篇 |
1980年 | 557篇 |
1979年 | 479篇 |
1978年 | 374篇 |
1977年 | 301篇 |
1976年 | 276篇 |
1975年 | 110篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
目的 对比研究朝鲜淫羊藿酸性多糖酯化还原前后的理化特性,并探讨其改善油酸诱导的肝癌HepG2细胞脂质堆积活性的差异。方法 采用高效凝胶渗透色谱法测定朝鲜淫羊藿酸性多糖(EFPA)的均一性和分子量,高效液相色谱法测定EFPA和酯化还原后朝鲜淫羊藿酸性多糖(EFPA-R)的单糖组成;采用油酸(OA)处理HepG2细胞诱导建立脂质蓄积模型,不同浓度EFPA与EFPA-R(10、30、100、300 μg·mL-1)分别和OA共同作用于细胞24 h,采用CCK-8试剂盒测定细胞存活率,油红O染色观察细胞内脂滴蓄积情况,并采用试剂盒测定细胞内总胆固醇(TC)、甘油三酯(TG)含量。结果 EFPA为成分均一的多糖组分,分子量为125.8 kDa,由甘露糖、葡萄糖、半乳糖、葡萄糖醛酸和阿拉伯糖组成,摩尔比为1.7∶7.4∶1.4∶1.8∶1.0,葡萄糖占比最大,EFPA-R由甘露糖、葡萄糖、半乳糖和阿拉伯糖组成,摩尔比为0.8∶10.6∶2.1∶1.0;在10-300 μg·mL-1范围内,EFPA和EFPA-R对HepG2细胞的抑制作用较弱,作为给药浓度;与空白组相比,模型组细胞中TC、TG含量显著升高(P < 0.01),细胞内红色脂滴显著增多,与模型组相比,EFPA可显著降低细胞中TC、TG含量(P < 0.01),明显减少细胞内红色脂滴(P < 0.05或P < 0.01),EFPA-R干预后细胞则无明显变化。结论 EFPA可明显改善HepG2细胞脂质堆积情况,且呈现剂量依赖性,而半乳糖醛酸(GalA)的存在可能是其抑制HepG2细胞脂质蓄积的关键因素。 相似文献
2.
3.
《Cancer cell》2022,40(2):153-167.e11
- Download : Download high-res image (229KB)
- Download : Download full-size image
4.
《Archivos de bronconeumología》2022,58(1):11-21
BackgroundWe aimed to describe the effectiveness and safety of inhaled antibiotics in chronic obstructive pulmonary disease (COPD) patients, as well as the patient profile in which they are usually prescribed and the patient groups that can most benefit from this treatment.MethodsMulticentre retrospective observational cohort study in COPD patients who had received ≥1 dose of inhaled antibiotics in the last 5 years. Clinical data from the two years prior to and subsequent to the start of the treatment were compared. Primary outcome: COPD exacerbations. Secondary outcomes: side effects, symptomatology (sputum purulence, dyspnoea), microbiological profile and pathogen eradication.ResultsOf 693 COPD patients analyzed (aged 74.1; 86.3% men; mean FEV1 = 43.7%), 71.7% had bronchiectasis and 46.6% presented chronic bronchial infection (CBI) by Pseudomonas aeruginosa (PA). After 1 year of treatment with inhaled antibiotics, there was a significant decrease in the number of exacerbations (?33.3%; P < .001), hospital admissions (?33.3%; P < .001) and hospitalization days (?26.2%; P = .003). We found no difference in effectiveness between patients with or without associated bronchiectasis. Positive patient outcomes were more pronounced in PA-eradicated patients. We found a significant reduction in daily expectoration (?33.1%; P = .024), mucopurulent/purulent sputum (?53.9%; P < .001), isolation of any potentially pathogenic microorganisms (PPM) (?16.7%; P < .001), CBI by any PPM (?37.4%; P < .001) and CBI by PA (?49.8%; P < .001). CBI by any PPM and ≥three previous exacerbations were associated with a better treatment response. 25.4% of patients presented non-severe side-effects, the most frequent of these being bronchospasm (10.5%), dyspnoea (8.8%) and cough (1.7%).ConclusionsIn COPD patients with multiple exacerbations and/or CBI by any PPM (especially PA), inhaled antibiotics appear to be an effective and safe treatment, regardless of the presence of bronchiectasis. 相似文献
5.
6.
7.
8.
9.
ObjectiveEach pulmonary segment is an anatomical and functional unit. However, it is fundamentally difficult to precisely distinguish every pulmonary segment using the conventional pulmonary intersegmental planes from computed tomography images. Building arteriopulmonary segments is likely to be an effective way to identify pulmonary segments.MethodsThe thoracic computed tomography images of 40 patients were collected. The anatomic structures of interest were extracted in the transverse, sagittal, and coronal planes using the semi-automated segmentation tools provided by Amira software. The intrapulmonary vessels were subsequently segmented and reconstructed. The distributions of the pulmonary arteries, veins, and bronchi were observed. In patients with pulmonary masses, the mass was also reconstructed.ResultsThe three-dimensional reconstructed images showed the branches of the pulmonary artery ramified up to their eighth order covering the entire lung as well as evident intersegmental gaps without pulmonary arteries. The segmental artery was closely accompanied by the segmental bronchi in 486 pulmonary segments (90% of total number of segments). The size and spatial location of the pulmonary mass within a pulmonary segment were also clearly visible.ConclusionsDemarcation of arteriopulmonary segments can be used to precisely distinguish every pulmonary segment and provide its detailed anatomical structure before pulmonary segmentectomy. 相似文献
10.